Translational analysis may also provide the foundations for future potential targeted exploitation, as to date the observed genomic differences in patients with PD-EP-NEC have not been meaningfully used in prospective randomised or non-randomised trials and treatment in the standard clinical setting remains chemotherapy, unless perhaps in the rare circumstances where tumour agnostic therapies are approved (e.g. targeting neurotrophic tyrosine receptor kinase, microsatellite instability, BRAF V600E).36 The gene discussed is BRAF; the disease is neuroendocrine carcinoma.